[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369978-105":59,"doc-detail-369978-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exploring-the-roles-of-cytochrome-p450-enzymes-and-their-inhibitors-in-cancers-and-non-neoplastic-human-diseases","Exploring the roles of cytochrome P450 enzymes and their inhibitors in cancers and non-neoplastic human diseases","","Cytochrome P450 (CYP) enzymes metabolize diverse compounds, including therapeutic drugs. CYP-generated metabolites are increasingly linked to disease pathogenesis and progression, especially cancer. Research investigates FDA-approved drugs as inhibitors of specific CYP isoforms and clarifies how these agents alter metabolic pathways of co-administered drugs. Such changes can modify therapeutic efficacy and safety, while CYP inhibitors also raise the likelihood of drug–drug interactions (DDIs), demanding careful clinical evaluation. This review analyzes the interplay among CYP inhibitors, their substrates, and resulting DDIs in cancers and non-neoplastic conditions, aiming to reduce adverse outcomes and improve treatment effectiveness.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-the-roles-of-cytochrome-p450-enzymes-and-their-inhibitors-in-cancers-and-non-neoplastic-human-diseases/369978/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-the-roles-of-cytochrome-p450-enzymes-and-their-inhibitors-in-cancers-and-non-neoplastic-human-diseases/369978.png","ImageObject",300,407,{"name":92,"@type":93},"kopisore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are cytochrome P450 (CYP) enzymes important in drug metabolism?","Question",{"text":112,"@type":113},"CYP enzymes are crucial for metabolizing various compounds, particularly therapeutic drugs, largely through Phase I monooxygenation reactions that use NADPH and a redox partner.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How can CYP inhibitors contribute to drug–drug interactions (DDIs)?",{"text":117,"@type":113},"CYP inhibitors significantly change substrate metabolism, which can alter the metabolic handling of co-administered agents and increase the risk of DDIs.",{"name":119,"@type":110,"acceptedAnswer":120},"What disease areas does the review address regarding CYP inhibitors?",{"text":121,"@type":113},"The review examines cancers and non-neoplastic diseases, including conditions such as allergies, depression, and stroke, focusing on the interplay between CYP inhibitors, substrates, and DDIs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369978,1790689636,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Archives of Pharmacal Research (2025) 48:1224–1252  \n[https://doi.org/10.1007/s12272-025-01581-x](https://doi.org/10.1007/s12272-025-01581-x)  \nOnline ISSN 1976-3786 Print ISSN 0253-6269  \nExploring the roles of cytochrome P450 enzymes and their inhibitors in cancers and non‑neoplastic human diseases  \nHyein Lee1 · Yeo‑Jung Kwon1 · Young‑Jin Chun1  \nReceived: 19 August 2024 / Accepted: 6 November 2025 / Published online: 18 November 2025 © The Author(s) 2025  \nAbstract  \nCytochrome P450 (CYP) enzymes are crucial for metabolizing various compounds, including therapeutic drugs. Metabolites generated through CYP-mediated pathways have been increasingly recognized as key contributors to the pathogenesis and progression of diverse diseases, particularly cancer. Consequently, ongoing research is examining Food and Drug Administration-approved drugs as potential inhibitors of specific CYP isoforms and characterizing their underlying mechanisms of action. These studies are essential for clarifying how approved drugs alter the metabolic pathways of co-administered agents, thereby influencing therapeutic efficacy and safety outcomes. CYP inhibitors significantly alter substrate metabolism, thereby increasing the risk of drug–drug interactions (DDIs). These interactions pose crucial challenges in clinical practice, necessitating careful evaluation when co-administering medications with similar metabolic pathways. Therefore, this review aims to examine the complex interplay among CYP inhibitors, their substrates, and DDIs in both cancers and non-neoplastic diseases, including allergies, depression, and stroke. The review seeks to minimize adverse outcomes and enhance therapeutic effectiveness by offering a comprehensive understanding of CYP inhibitors.  \nKeywords Cytochrome P450 (CYP) · Drug metabolism · Cancer · Inhibitor · Drug–drug interaction (DDI)  \nIntroduction  \nVarious types of enzymes orchestrate a broad range of metabolic processes in organisms, including humans. Enzyme inhibitors bind enzyme active sites to modulate their catalytic activity, offering potential treatments for diverse diseases (Copeland et al. 2007) . The clinical use of numerous enzyme inhibitors underscores the importance of enzymes as viable drug targets (Copeland 2005). Several key enzymes involved in cellular and drug metabolism have emerged as promising therapeutic targets for diseases with limited effective treatment options (Robertson 2005; Orhan 2019; Zhao et al. 2021) .  \nHyein Lee and Yeo-Jung Kwon these authors contributed equally to this work.  \n* Young-Jin Chun [yjchun@cau.ac.kr](yjchun@cau.ac.kr)  \n1 College of Pharmacy and Center for Metareceptome Research, Chung-Ang University, 84 Heukseok-Ro, Dongjak-Gu, Seoul 06974, Republic of Korea  \nCytochrome P450s (CYPs or P450s) are hemoproteins that contain a single heme prosthetic group within their active sites (Scott and Halpert 2005) . The human CYP family plays a critical role in Phase I drug metabolism, predominantly by catalyzing monooxygenation reactions (Nebert and Dalton 2006) . In these reactions, one oxygen atom is incorporated into the substrate, typically a hydrocarbon, while the other is reduced to form water. These reactions require the electron donor nicotinamide adenine dinucleotide phosphate (NADPH) and redox partner, such as NADPH–P450 reductase which transfers reducing equivalents to the CYP heme iron during catalysis (Durairaj and Li 2022) (Fig. 1) . While CYPs share structural similarities and conserved mechanisms of action, their active sites vary considerably, accounting for substrate specificity (Table 1) . CYPs are essential for metabolizing endogenous and exogenous substrates, including drugs, environmental chemicals, and natural products (Scott and Halpert 2005). Despite facilitating detoxification, CYP enzymes can also generate toxic metabolites, increasing cancer risk (Nebert and Dalton 2006) . Specifically, reaction uncoupling in the CYP oxidation cycle produces reactive o","cbCaiuFNBpjZImMF","https://ap.wps.com/l/cbCaiuFNBpjZImMF","pdf",1566285,29,"English","# Abstract\n# Introduction\n# Cytochrome P450 enzymes in human drug metabolism\n## Phase I monooxygenation and redox partners\n## Structural diversity and substrate specificity\n# CYP-mediated toxicity and disease links\n# Translational cancer research and targeted prodrug strategies\n# CYP involvement in non-neoplastic diseases","[{\"question\":\"Why are cytochrome P450 (CYP) enzymes important in drug metabolism?\",\"answer\":\"CYP enzymes are crucial for metabolizing various compounds, particularly therapeutic drugs, largely through Phase I monooxygenation reactions that use NADPH and a redox partner.\"},{\"question\":\"How can CYP inhibitors contribute to drug–drug interactions (DDIs)?\",\"answer\":\"CYP inhibitors significantly change substrate metabolism, which can alter the metabolic handling of co-administered agents and increase the risk of DDIs.\"},{\"question\":\"What disease areas does the review address regarding CYP inhibitors?\",\"answer\":\"The review examines cancers and non-neoplastic diseases, including conditions such as allergies, depression, and stroke, focusing on the interplay between CYP inhibitors, substrates, and DDIs.\"}]","Exploring the roles of cytochrome P450 enzymes and their inhibitors in cancers and non-neoplastic human diseases | PDF",1790185970,73,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b045202fb923156d5c0d742444e37967.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a6b4591ba31e7c17b7c41cf8ffd42dd.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7006d51f6a7aba01ab178bbfe9347605.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5bdef6788b5ef08cdf757b3fdb2071b4.webp",980,1301]